Identification and structural insight of an effective PPARγ modulator with improved therapeutic index for anti-diabetic drug discovery
作者:Haowen Jiang、X. Edward Zhou、Jingjing Shi、Zhi Zhou、Guanguan Zhao、Xinwen Zhang、Yili Sun、Kelly Suino-Powell、Lei Ma、Hui Gao、Xiyong Yu、Jia Li、Jingya Li、Karsten Melcher、H. Eric Xu、Wei Yi
DOI:10.1039/c9sc05487a
日期:——
proliferator-activated receptor γ (PPARγ) is a key regulator of glucose homeostasis and lipid metabolism, and an important target for the development of modern anti-diabetic drugs. However, current PPARγ-targeting anti-diabetic drugs such as classical thiazolidinediones (TZDs) are associated with undesirable side effects. To address this concern, we here describe the structure-based design, synthesis, identification
过氧化物酶体增殖物激活受体γ(PPARγ)是葡萄糖稳态和脂质代谢的关键调节剂,并且是开发现代抗糖尿病药物的重要目标。但是,当前的靶向PPARγ的抗糖尿病药物,例如经典的噻唑烷二酮(TZDs)与不良副作用相关。为了解决这一问题,我们在此描述基于结构的设计,合成,鉴定以及详细的体内和体外实验新型基于癸酸(DA)的选择性PPARγ调节剂(SPPARγM)VSP-77,特别是(S)-VSP-77的特性,作为开发改进和更安全的抗糖尿病治疗剂的潜在“命中点” 。我们还确定了PPARγ配体结合域(LBD)与(S)-VSP-77的两个分子的复合晶体结构,这揭示了以前未公开的变构结合模式。总体而言,这些发现不仅证明了(S)-VSP-77相对于目前的TZD药物和代表性的部分激动剂INT131的治疗优势,而且为将来开发SPPARγMs作为安全,高效的抗糖尿病药物提供了合理的基础。